此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0) (PARTNER-MH)

2026年6月12日 更新者:VA Office of Research and Development
The proposed project is a randomized controlled trial that seeks to test the effectiveness of a peer-facilitated, patient navigation program to improve mental healthcare experiences and outcomes for under-supported Veterans from diverse cultural backgrounds and communities. PARTNER-MH is a structured, telehealth-based intervention delivered by VHA peer specialists over a three-month period. It integrates two evidence-based care delivery models, peer support and patient navigation, and addresses three primary contributors to healthcare disparities: unmet social needs, low patient engagement in care, and unproductive patient-clinician communication. Findings from this study will support ongoing efforts to improve mental health services for all Veterans in the VHA.

研究概览

详细说明

Despite expanded availability of mental health services within the Veterans Health Administration (VHA), many Veterans-particularly those from varied cultural backgrounds and communities-continue to face significant barriers to accessing and fully engaging in care. Effective strategies to address these issues remain limited, leaving under-supported and vulnerable Veterans at risk for inadequate care experiences and poorer mental health outcomes. If these persistent and often overlooked challenges remain unresolved, they will continue to contribute to long-term disability, societal burden, and costly, inefficient care.

To address these challenges, the investigators will test the effectiveness of the Pro-Active, Treatment Navigation to Engage Racially Diverse Veterans in Mental Healthcare (PARTNER-MH) intervention. PARTNER-MH integrates two existing evidence-based care models: peer services and patient navigation and offers multiple services to address key drivers of healthcare disparities. These include (a) peer support, (b) assessment of unmet social needs to address barriers to care, (c) patient navigation to facilitate access to and engagement in mental health services, d) and psychoeducation to increase self-efficacy to communicate with providers. The intervention will be delivered via telehealth over 3 months by VHA peer specialists.

Specific Aims: This study is a multisite, randomized controlled clinical trial comparing PARTNER-MH to an educational brochure control group. Aim1: Test the effects of PARTNER-MH on mental health functioning (primary outcome), measured by the Veterans RAND-12 Mental Health Summary Score (VR-12 MCS), and secondary outcomes (e.g., depression, anxiety, PTSD, and healthcare utilization) at 3 months (primary endpoint) and 6 months (sustained effects) from baseline compared to the control group. Aim2: Test the effects of PARTNER-MH on mental healthcare process outcomes (patient engagement, communication self-efficacy) at 3 and 6 months. Aim3: To inform PARTNER-MH's future implementation, maintenance, and tailoring to different patient characteristics, we will conduct a formative process evaluation, guided by the Consolidated Framework for Implementation Research (CFIR), using mixed methods and input from Veteran, provider, and operational partners.

Methodology: Aims 1 and 2 involve delivering the intervention to (N=268) minoritized Veterans in outpatient mental health clinics at the Richard L. Roudebush VA Medical Center and the VA Pittsburgh Healthcare System. Data from Aims 1 and 2 will be analyzed using linear mixed models. In Aim 3, the investigators will describe Veterans' (n=30) and providers' experiences (N=10) with the intervention using semi-structured interviews to identify barriers and facilitators to PARTNER-MH's future implementation. The investigators will explore sex and post-traumatic stress disorder (PTSD) diagnosis as potential moderators. Communication's self-efficacy and patient engagement will be examined as mediators. The investigators will conduct Coincidence Analysis to explore which patients benefits the most from the intervention and which sets of intervention conditions are sufficient or necessary to lead to study outcomes. Qualitative data will be analyzed using an inductive/deductive approach. Mixed methods data will be integrated using joint displays.

研究类型

介入性

注册 (估计的)

268

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Indiana
      • Indianapolis、Indiana、美国、46202-2884
        • Richard L. Roudebush VA Medical Center, Indianapolis, IN
        • 接触:
        • 首席研究员:
          • Johanne Eliacin, PhD
        • 接触:
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15240
        • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Member of a racial or ethnic minoritized group
  • Veterans who are currently receiving or waiting to receive treatment in the outpatient mental health clinics or affiliated CBOCS at the study sites
  • Eligible participants must be:

    • waiting to start treatment (e.g., Veterans who were referred to treatment, assigned a provider, or recommended a treatment option that includes either pharmacotherapy, psychotherapy, or both but have not yet started treatment at time of enrollment)
  • Veterans who are already receiving ongoing treatment - pharmacotherapy, individual, and/or group psychotherapy, but initiated treatment within 9 months of study enrollment date
  • Have a diagnosis of depression, anxiety, or PTSD
  • Not currently receiving peer services in the outpatient clinic

Exclusion Criteria:

  • Patients needing emergency psychiatric services of hospitalization due to suicidal ideation or recent suicide attempt (within past 2 months), have severe psychiatric symptoms (e.g., active psychosis), or a diagnosis of severe mental illness (e.g., schizophrenia)
  • Severe cognitive, hearing, or speech impairment (e.g., dementia, severe TBI)
  • Severe physical illness that impedes study participation
  • Recent hospitalization for substance use disorder (SUD) for the past 2 months or severe SUD symptoms based on the screen tools (AUDIC-C, DAST-10) that may require higher level of care and peer support

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:卫生服务研究
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention condition
Arm 1 involves delivery of the study intervention, PARTNER-MH program.
PARTNER-MH is a manualized, peer-facilitated, patient navigation intervention that involves the delivery of three services: 1) peer support to increase patient engagement in care, 2) patient navigation to address unmet social needs and increase access to services, and 3) psychoeducation to increase communication self-efficacy. PARTNER-MH consists of 10 sessions, lasting up to 60 minutes, that will be delivered over 12 weeks via videoconference or phone. It also includes a rapport building/orientation session that will be delivered in person or via videoconference to facilitate study engagement and two flex weeks with no scheduled lessons to accommodate rescheduling if needed.
有源比较器:Control condition
Participants in this arm will receive the control condition, which consists of informational/education materials.
The control condition consists of informational/educational materials that will be distributed to study participants after randomization and completion of baseline assessment. The content of the educational brochure includes 3-4 brief, healthy living articles about stress management, well-being, and navigation of health services.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The Veterans RAND 12 Item Health Survey (VR-12), mental health composition score (6-items, MCS)
大体时间:baseline, 3 and 6 months
The Veterans RAND 12-item (VR-12) is a brief, multi-use, self-administered survey that is used primarily to assess health-related quality of life, to estimate disease burden, and to evaluate disease-specific benchmarks with other populations. The 12 items in the questionnaire correspond to eight principal physical and mental health domains including general health perceptions; physical functioning; role limitations due to physical and emotional problems; bodily pain; energy-fatigue, social functioning and mental health. The 12 items are summarized into two scores, a "Physical Health Summary Measure {PCS-physical component score}" and a "Mental Health Summary Measure {MCS-mental component score}". VR-12 scores are standardized using a T-score metric ranging from 1-100, with a mean of 50 and a standard deviation of 10. Scores below 50 indicate worse mental health than the general population average.
baseline, 3 and 6 months

次要结果测量

结果测量
措施说明
大体时间
Patient Health Questionnaire-9 (PHQ-9)
大体时间:baseline, 3 and 6 months
The PHQ-9 is a 9-item self-administered questionnaire that assesses cases of depression and symptom severity. Each question is scored from 0 to 3, with total scores ranging from 0 to 27. Higher scores indicate greater depression severity. Scores are categorized as: minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). The questionnaire has high internal consistency, reliability (α = 0.89), good sensitivity, and specificity.
baseline, 3 and 6 months
Generalized Anxiety Disorder-7 (GAD-7)
大体时间:baseline, 3 and 6 months
GAD-7 is a validated self-reported measure of anxiety. It has 7 items rated on a 4-point Likert scale, 0 (Not at all) to 3 (Nearly every day). The scale has a total summed score of 0 (minimum) to 21 (maximum). It has shown reliability, internal consistency (α = 0.89), and good sensitivity. A meaningful change is indicated by 5 or more points. A total score of 1-4 indicates minimal symptoms, 5-9 mild symptoms, 10-14 moderate symptoms, and 12-21 severe symptoms.
baseline, 3 and 6 months
PTSD symptoms -Life Event Checklist (PCL-5)
大体时间:baseline, 3 and 6 months
The PCL-5 is a widely used, 20-item self-report questionnaire used to screen for and diagnose probable PTSD. It evaluates the presence and severity of PTSD symptoms over the past month. The scale has strong internal consistency α =.94, test-retest reliability, convergent and discriminant validity. Items are rated on a 5-point Likert scale, ranging from 0 (not at all) to 4 (extremely). All items are summed to create a total score that ranges from 0 to 80. Higher scores reflect a greater degree of distress or severity of PTSD symptoms. The recommended optimal cut-off score of >33 will be used to indicate probable PTSD.
baseline, 3 and 6 months
Altarum Consumer Engagement (ACE) scale
大体时间:baseline, 3 and 6 months
Patient Engagement will be measured with the Altarum Consumer Engagement (ACE) scale, which has 12 items and 3 subscales to reflect patients' commitment to everyday health behaviors, navigation skills in using healthcare services, and informed choice in treatment decisions. The ACE is administered as a 5-point Likert scale, and scores range from 5 to 25. Higher scores represent higher patient engagement.
baseline, 3 and 6 months
Perceived Efficacy in Patient-Physician Interaction scale (PEPPI-5)
大体时间:baseline, 3 and 6 months
Communication self-efficacy will be measured with the Perceived Efficacy in Patient-Physician Interaction scale (PEPPI-5), a 5-item scale scored on a 5-point Likert scale ranging from 1 (not confident at all) to 5 (very confident). Higher scores indicate higher levels of communication self-efficacy. The PEPPI-5 has demonstrated high internal consistency (α= 0.92) and adequate test-retest reliability.
baseline, 3 and 6 months

其他结果措施

结果测量
措施说明
大体时间
Working Alliance Inventory Short-Revised (WAI-SR)
大体时间:baseline, 3 and 6 months
Working Alliance Inventory Short-Revised (WAI-SR) evaluates key aspects of the therapeutic alliance between patients and their providers. It includes 12 items rated on a 5-point Likert scale ranging from 1= never to 5= always. It showed high reliability (α> 0.90). Higher scores correspond to higher working alliance.
baseline, 3 and 6 months
Multi-Dimensional Treatment Satisfaction Measure (MDSTM)
大体时间:baseline, 3 and 6 months
Multi-Dimensional Treatment Satisfaction Measure (MDSTM) has 2 sections, 11 subscales, and comprehensively assesses satisfaction with treatment. For this study, the investigators will use 4 subscales (12-items) that include 1) suitability and 2) utility of treatment, 3) attitudes toward treatment, and 4) therapist interpersonal style. Response options are rated on a 5-point Likert scale ranging from not at all (0) to very much (4), with scores indicating higher satisfaction. The measure shows satisfactory reliability (Cronbach's alpha α ≥ .70 for subscales).
baseline, 3 and 6 months
Assessing Circumstances and Offering Resources for Needs (ACORN)
大体时间:baseline, 3 and 6 months
ACORN a 15-item, self-administered screening tool for health related unmet social needs. Most items have a yes or no answer. Two items - loneliness/social isolation and experience of abuse have answer options of "never, rarely, sometimes, often, and always." One item related to employment has answer option of "yes, help finding work, yes, help keeping work, and I do not need or want help."
baseline, 3 and 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Johanne Eliacin, PhD、Richard L. Roudebush VA Medical Center, Indianapolis, IN

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2027年1月4日

初级完成 (估计的)

2029年9月28日

研究完成 (估计的)

2031年12月31日

研究注册日期

首次提交

2026年6月8日

首先提交符合 QC 标准的

2026年6月8日

首次发布 (实际的)

2026年6月12日

研究记录更新

最后更新发布 (实际的)

2026年6月16日

上次提交的符合 QC 标准的更新

2026年6月12日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • HSR2-001-24W
  • I01RD000506-01A2 (其他标识符:Veterans Health Administration)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅